Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company specializing in gastrointestinal (GI) treatments, has announced its participation in two upcoming investor conferences in September 2024:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, from September 4-6, where management will engage in one-on-one meetings.
2. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, on September 9. Management will participate in a fireside chat at 12:00 pm ET and conduct one-on-one meetings throughout the day.
A live webcast and 90-day archived recording of the fireside chat will be available on Phathom's website in the News & Events section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PHAT gained 0.56%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
- Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Management will participate in one-on-one meetings throughout the conference, which runs from Wednesday, September 4 to Friday, September 6, 2024.
- H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. Management will participate in a fireside chat on Monday, September 9, 2024, at 12:00 pm ET and one-on-one meetings throughout the day.
To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
What investor conferences will Phathom Pharmaceuticals (PHAT) attend in September 2024?
When is Phathom Pharmaceuticals' (PHAT) fireside chat at the H.C. Wainwright conference?
How can investors access Phathom Pharmaceuticals' (PHAT) fireside chat webcast?
How long will the recording of Phathom Pharmaceuticals' (PHAT) fireside chat be available?
What is Phathom Pharmaceuticals' (PHAT) focus in the biopharmaceutical industry?
